Case Studies
Budget Impact Model
Project: Budget Impact Model
Client: Major US Pharma
Problem
Client was looking for an easy way to demonstrate to Payers budget impact of a new drug.
Result
Payers agreed to cover a new drug.
Markov Model
Project: Markov Model
Client: Major Global Biotech
Problem
Client was looking for a simple way to help seek FDA approval on Phase 3 drug to enter Phase 4. Problem was to communicate new approach to drug administration. Our user friendly interactive software model allowed decision makers with no health economic background to easily comprehend new drug benefits for patients.
Result
FDA approved new drug for Phase 4 research.
Interactive Medical Device User Manual
Project: Interactive Medical Device User Manual
Client: Major Global Pharma
Problem
Client was facing a challenge to explain new medical device operation to a diverse audience, including caregivers, trainers, biomedical engineers, sales personnel, government regulators and patients themselves.
Result
Our interactive presentation provided the practicality of viewing instructions on the Web and on an interactive CD-ROM packaged with the product.
HIV Tracking Website
Project: HIV Tracking Website
Client: Major UK Pharma
Problem
Client had access to nationwide data centers receiving real-time updates on disease progression. Client wanted to communicate in a user friendly fashion real-time tracking results to doctor and patient communities.
Result
Client was able to provide communities with real-time UK Map tracking of a disease.
Depression (MDD) CE Model
Project: Depression (MDD) Cost-Effectiveness Model / Substitution Analysis
Client: Major EU Pharma
Problem
Client was looking for a pricing and reimbursement econometric model. Problem was to communicate efficacy and additional benefits of a new anti-depression drug. Our user friendly interactive software model allowed users with no health economic background to easily understand efficacy of a new drug and additional benefits for patients.
Result
Danish, German, Turkish Government approved a new drug for 100% coverage.